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S U M M A R Y
Introduction: Bacterial infection is one of the major causes of death in patients with thalassemia. Clinical
predictive factors for severe bacterial infection were evaluated in patients with non-transfusion-
dependent thalassemia (NTDT).
Methods: A retrospective study was conducted of patients with NTDT aged 10 years at Srinagarind
Hospital, Khon Kaen University, Thailand. Clinical characteristics and potential clinical risk factors for
bacterial infection were collected. Risk factors for bacterial infection were evaluated by multivariate
logistic regression analysis.
Results: A severe bacterial infection was found in 11 of the total 211 patients with NTDT (5.2%). None of
the clinical factors assessed was shown to be statistically associated with severe bacterial infection in
patients with NTDT. However, three factors were demonstrated to be potential predictive factors for
severe bacterial infection: time after splenectomy >10 years, deferoxamine therapy, and serum ferritin
>1000 ng/ml. None of the patients died from infection.
Conclusion: The prevalence of bacterial infection in patients with NTDT was found to be moderate. Time
after splenectomy >10 years, deferoxamine therapy, and iron overload may be clinical risk factors for
severe bacterial infection in patients with NTDT. Bacterial infection should be recognized in
splenectomized patients with NTDT, particularly those who have an iron overload.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Thalassemia is the most common genetic disorder worldwide. The
prevalence is high among populations in the Mediterranean region,
Africa, and Southeast Asia. Thalassemia syndrome can be classiﬁed
into three subgroups according to the severity of clinical presenta-
tion: thalassemia major, thalassemia intermedia, and thalassemia
minor. Non-transfusion-dependent thalassemia (NTDT) is a term
used to describe the group of patients with thalassemia who do not
require lifelong regular blood transfusions for survival, but who may
need an occasional blood transfusion in some situations, e.g.,
pregnancy, an operation, or infection.1
Infection is one of the major causes of death in patients with
thalassemia.2–4 The prevalence of infection in patients with* Corresponding author. Division of Hematology, Department of Internal
Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,
Thailand. Tel: +66 43363664; fax: +66 43204159.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).thalassemia varies from 22.5% to 66%.5–9 The mechanisms
resulting in the increase in susceptibility to infection in these
patients10 include (1) impaired chemotaxis and phagocytosis of
macrophages and neutrophils,11,12 (2) alteration in T-lympho-
cyte subsets,13,14 (3) decreased numbers and activity of natural
killer cells,15 (4) increased numbers and activity of B lympho-
cytes,14,16 and (5) impaired immunoglobulin secretion and the
suppression of complement system function.17 Many clinical
risk factors for bacterial infection in patients with thalassemia
have been reported in the literature, including splenectomy,
iron overload, severe anemia, facial deformities, and gall-
stones.5,8,9,18,19
Most of the studies on bacterial infections in patients with
thalassemia have focused on those patients with thalassemia
major. Information on the prevalence of infection and clinical risk
factors in patients with NTDT remains limited. The aim of this
study was to determine the prevalence and associated factors for
severe bacterial infection in patients with NTDT.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Demographic and clinical characteristics of the 211 patients with non-transfusion-
dependent thalassemia
Characteristics Patients (N = 211)
Age at enrollment, years, mean  SD 25.9  13.3
Age at ﬁrst diagnosis, years, mean  SD 8.2  12.6
Age at ﬁrst transfusion, years, mean  SD 9.5  13.5
Transfusion index, ml/kg/6 months, mean  SD 19.1  19
Hemoglobin, g/dl, mean  SD 7.9  1.2
Platelet count, 109/l, mean  SD 383.5  242.7
Serum ferritin, ng/ml, mean  SD 1692.3  1759
Time after splenectomy, years, mean  SD 4.2  7.5
Gender, n (%)
Female 119 (63.5)
Male 92 (36.5)
Splenectomy, n (%)
No 134 (61.1)
Yes 77 (38.9)
Previous bacterial infection, n (%)
No 200 (94.8)
Yes 11 (5.2)
Current iron chelation, n (%)
No 78 (37)
Deferoxamine 22 (10.4)
Deferiprone 79 (37.4)
Deferasirox 3 (1.4)
Combined deferoxamine + deferiprone 29 (13.8)
Genotype group, n (%)
b-thalassemia/Hb E 127 (60.2)
Hb H disease 10 (4.7)
Hb H disease with Hb CS 24 (11.5)
Hb H disease with Hb Pakse´ 4 (1.9)
EABart’s diseasea 14 (6.6)
EABart’s disease with Hb CSb 26 (12.4)
EFBart’s disease with Hb CSc 2 (0.9)
EABart’s disease with Hb Pakse´d 2 (0.9)
EFBart’s diseasee 2 (0.9)
SD, standard deviation; Hb CS, hemoglobin constant spring; Hb Pakse´, hemoglobin
Pakse´.
a Compound heterozygous Hb H and heterozygous Hb E.
b Compound heterozygous Hb H with Hb CS and heterozygous Hb E.
c Compound heterozygous Hb H with Hb CS and homozygous Hb E.
d Compound heterozygous Hb H with Hb Pakse´ and heterozygous Hb E.
e Compound heterozygous Hb H and homozygous Hb E.
Table 2
Characteristics of bacterial infections in 11 patients with non-
transfusion-dependent thalassemia
Bacterial infections Patients (n = 11)
Organisms, n (%)
Klebsiella species 4 (36.4)
Burkholderia pseudomallei 3 (27.2)
Escherichia coli 1 (9.1)
Aeromonas sobria 1 (9.1)
Stenotrophomonas maltophilia 1 (9.1)
Group B Streptococcus 1 (9.1)
Site of infection, n (%)
Septicemia 7 (63.6)
Meningitis 1 (9.1)
Abscess (spleen, lymph node) 3 (27.3)
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A retrospective study was conducted of patients with NTDT in
the thalassemia registry of the ‘‘Epidemiologic Study of Major
Complications in Adult and Adolescent Patients with Thalassemia
in Northeastern Thailand’’ study (E-SAAN study). Eligible partici-
pants were thalassemic patients aged 10 years. Severe bacterial
infection was deﬁned as a bacterial infection necessitating
hospitalization and intravenous antibiotic administration. The
clinical presentations and laboratory data, including those of
potential risk factors for bacterial infection indicated in the
literature, were collected. Bacterial infection was conﬁrmed by the
isolation of pathogens from blood, pus, stool, cerebrospinal ﬂuid
(CSF), and other body ﬂuids. Serum ferritin levels were the mean
serum ferritin levels from the last 6 months of data.
The research protocol was approved by the Ethics Review Board
of the Faculty of Medicine, Khon Kaen University.
2.1. Statistical analysis
Continuous parameters were reported as the mean and
standard deviation (SD). Categorical parameters were reported
as the number and percentage. Clinical predictive factors for
bacterial infection were analyzed by univariate and multivariate
logistic regression methods. All statistical analyses were per-
formed using STATA program version 10 (StataCorp, College
Station, TX, USA). A probability value of less than 0.05 was
considered statistically signiﬁcant.
3. Results
The records of a total of 211 patients (119 females, 92 males)
were reviewed. Severe bacterial infections were found in
11 patients (5.2%). The baseline clinical characteristics of the
211 patients are summarized in Table 1. The mean age at the time
of enrollment was 25.9 years. Seventy-seven patients (36.5%) had
undergone a splenectomy, with the mean duration of time since
the splenectomy of 4.2 years. None of the splenectomized patients
in this study had received prophylactic antibiotics after the
splenectomy. One hundred and thirty-three patients had received
and were receiving iron chelation therapy. Deferiprone was the
most common iron chelation treatment (n = 79, 37.4%), followed by
a combination of deferoxamine and deferiprone (n = 29, 13.8%) and
deferoxamine alone (n = 22, 10.4%). None of the patients in this
cohort had experienced neutropenia due to the use of deferiprone.
The schedule for monitoring neutropenia was every week for the
ﬁrst month, followed by every 4–6 weeks, in accordance with the
local practice at the Khon Kaen University hospital. The mean
hemoglobin level was 7.9 g/dl and the mean serum ferritin was
1692.3 ng/ml.
Table 2 shows a summary of the causative organisms and sites
of infection in the 11 infected patients. Of these 11 patients with
12 episodes of infection, Klebsiella species were the most common
causative organisms (n = 4, 36.4%), followed by Burkholderia
pseudomallei (n = 3, 27.2%). Septicemia was the most common site
of infection (n = 7, 63.6%), followed by abscesses of the spleen and
lymph nodes (n = 3, 27.3%). One patient had two episodes of
infection, which were abscesses of the parotid gland and lymph
nodes; the causative organisms were Klebsiella species in both
episodes. One splenectomized patient had group B streptococcal
meningitis. This patient received the pneumococcal vaccine before
undergoing splenectomy, however she did not receive any further
vaccinations after the splenectomy. Of the 11 infected patients,
only one (9.1%) received prophylaxis vaccinations prior to
splenectomy. None of the patients in this cohort died frominfection. A summary of the clinical characteristics of the
11 infected patients with NTDT is shown in Table 3.
The univariate analysis of risk factors for bacterial infection in
patients with thalassemia is shown in Table 4. Serum ferritin
>1000 ng/ml (odds ratio (OR) 8.3, 95% conﬁdence interval (95% CI)
1.1–69; p = 0.04), time after splenectomy >10 years (OR 4.0, 95% CI
1.1–14; p = 0.02), and deferoxamine therapy (OR 4.1, 95% CI 1.2–
14; p = 0.02) were statistically signiﬁcant for bacterial infection.
The multivariate analysis of risk factors for bacterial infection in
patients with thalassemia is shown in Table 5. None of the clinical
Table 3
Clinical characteristics of 11 infected patients with non-transfusion-dependent thalassemia
No. Age
(years)/ sex
Hb (g/dl) Ferritin
(ng/ml)
Splenectomy
(time after splenectomy)
Organism Site of infection
1. 36/F 8.2 1128 No Burkholderia pseudomallei Septicemia
2. 33/M 10.8 1250 No Burkholderia pseudomallei Splenic abscess
3. 23/M 6.8 8020 Yes (14 years) Aeromonas sobria Septicemia
4. 27/M 6.1 400 Yes (21 years) Group B Streptococcus Meningitis
5. 30/F 6.7 1410 Yes (24 years) Klebsiella species Lymph node abscess
6. 52/M 6.9 1965 No Escherichia coli Septicemia
7. 30/F 6.6 7883 No Klebsiella species Septicemia
8. 22/M 8.4 9999 Yes (15 years) Stenotrophomonas maltophilia Septicemia
9. 22/F 8.1 1646 Yes (13 years) Burkholderia pseudomallei Septicemia
10. 16/F 8.2 1959 No Klebsiella species Septicemia
11. 16/F 8.1 1756 Yes (11 years) Klebsiella species Lymph node abscess
F, female; M, male.
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multivariate logistic regression analysis.
4. Discussion
The prevalence of severe bacterial infection was found to be
moderate in patients with NTDT (5.2%). Time after splenectomy
>10 years, deferoxamine therapy, and serum ferritin >1000 ng/ml
may be clinical risk factors for severe bacterial infection in patients
with NTDT.
It is well established that iron overload is an important
predisposing factor for bacterial infection. The mechanism for this
might be an impairment of phagocytic activity of macrophages and
neutrophils and alteration of T-lymphocyte cell subsets resultingTable 4
Univariate analysis of risk factors for bacterial infection in 211 patients with non-
transfusion-dependent thalassemia
Variables Number
(N = 211)
% of
infection
(n = 11)
OR 95% CI p-Value
Age (every increase
in 1 year)
- - 0.9 0.9–1.1 0.9
Gender
Female 119 46.1 0.6 0.2–1.9 0.4
Male 92 53.9 1 - -
Splenectomy
No 134 45.5 1 - -
Yes 77 54.5 2.2 0.6–7.4 0.2
Time after splenectomy >10 years
No 172 54.5 1 -
Yes 39 45.5 4.0 1.1–14 0.02
Hemoglobin 7 g/dl
No 159 63.6 1 - -
Yes 52 36.4 1.8 0.5–6.4 0.3
Thalassemic facies
No 151 54.5 1 - -
Yes 60 45.5 0.4 0.1–1.5 0.2
Serum ferritin >1000 ng/ml
No 92 9.1 1 - -
Yes 119 90.9 8.3 1.1–66 0.04
Deferoxamine therapy
No 160 45.5 1 - -
Yes 51 54.5 4.1 1.2–14 0.02
Deferiprone therapy
No 132 54.5 1 - -
Yes 79 45.5 1.4 0.4–4.8 0.5
b-thalassemia
No 84 27.2 1 - -
Yes 127 72.8 1.8 0.4–7.0 0.38
Vaccination
No 163 90.9 1 - -
Yes 37 9.1 0.4 0.05–3.5 0.4
OR, odds ratio; 95% CI, 95% conﬁdence interval.in immune system abnormalities.20,21Moreover, iron overload also
increases the apparent virulence of some bacteria, for example
Yersinia enterocolitica, Klebsiella species, Pseudomonas aeruginosa,
Escherichia coli, Streptococcus pneumoniae, Listeria monocytogenes,
and Legionella pneumophila. This study also demonstrated that
serum ferritin >1000 ng/ml may be a signiﬁcant clinical risk factor
for bacterial infection in patients with NTDT.
Splenectomized patients are known to have an increased
susceptibility to infection, particularly from encapsulated bacteria.
The duration of time since the splenectomy is a strong risk factor
for bacterial infection. Supporting this, Rahav et al. showed that
time after splenectomy >10 years had an adjusted rate of infection
as high as 15.6 per 100 patient-years (p = 0.0052).9 In the present
cohort, it was found that time after splenectomy >10 years
increased the risk of bacterial infection with an OR of 4.0 (95% CI
1.1–14; p = 0.02); however on multivariate analysis, time after
splenectomy did not show a statistically signiﬁcant association
with bacterial infection. This ﬁnding might be due to the small
number of events and sample size.
Vaccination prior to splenectomy surgery was noted in
38 patients (49.3%). There are two main possible reasons for the
low percentage of vaccination prior to splenectomy in this study:
(1) the patients’ healthcare insurance did not cover the vaccine
cost, so the patients would have had to pay for themselves, and (2)
the vaccines only became available in the Khon Kaen University
hospital in 2005, therefore patients who underwent splenectomy
before 2005 did not receive vaccinations. Nevertheless, vaccination
was not associated with a decreased risk of bacterial infection in
patients with NTDT. The infections seen in this patient population
were not preventable with vaccinations given prior to splenecto-
my.
Klebsiella species were the most common causative organisms
in this study. This ﬁnding is in agreement with those of previous
studies in Asian patients with thalassemia.5,22 However, the result
is different from those of studies performed in Western countries,
where Yersinia species have been identiﬁed as the most common
causative organisms in patients with thalassemia.23–25 Previous inTable 5
Multivariate analysis of risk factors for bacterial infection in 211 patients with non-
transfusion-dependent thalassemia
Variables AOR 95% CI p-Value
Serum ferritin >1000 ng/ml 5.6 0.6–51.5 0.1
Deferoxamine therapy 1.8 0.4–7.7 0.4
Time after splenectomy >10 years 2.5 0.5–11.1 0.2
Hemoglobin 7 g/dl 1.1 0.2–4.3 0.9
Thalassemic facies 0.6 0.2–2.5 0.5
b-thalassemia 0.6 0.1–3.2 0.5
AOR, adjusted odds ratio; 95% CI, 95% conﬁdence interval.
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by deferoxamine therapy.23
Deferoxamine therapy is one of the clinical factors for severe
bacterial infection, especially due to Yersinia enterocolitica, in
Western countries.23–26 This study also demonstrated that
deferoxamine therapy is one of the clinical factors that is
potentially associated with severe bacterial infection. On multi-
variate analysis, however, deferoxamine therapy did not show a
statistically signiﬁcant association with bacterial infection, which
might be due to the small number of events. Deferiprone, the most
common iron chelating agent in this study, was not associated with
bacterial infection. This ﬁnding is in agreement with those of
previous studies that have found deferiprone not to enhance the
growth of pathogenic organisms in patients with thalassemia.23,26
Northeastern Thailand is an area endemic for B. pseudomallei. A
previous study has shown that thalassemia is one of the signiﬁcant
clinical risk factors for B. pseudomallei infection.27 The mechanism
of the increased susceptibility to this infection in patients with
thalassemia remains unclear.
A limitation of this study is that serum ferritin was used to
evaluate iron overload instead of liver iron concentrations by
magnetic resonance imaging technology. Serum ferritin may not
reﬂect the true iron excess in these patients; however, recent
studies have shown a good correlation between serum ferritin
>800 ng/ml and liver iron concentration (LIC) 5 mg Fe/g dw, the
level used to initiate chelation therapy, with a positive predictive
value of 91.7%.28
In conclusion, iron overload, a time after splenectomy >10
years, and deferoxamine therapy may be risk factors for severe
bacterial infection in patients with NTDT. Evaluation for iron
excess should be performed regularly in patients with NTDT. Early
recognition of bacterial infection in patients with NTDT may
reduce morbidity and mortality, especially in those splenecto-
mized patients with iron overload.
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